Wells Fargo analyst Larry Biegelsen downgraded Tandem Diabetes (TNDM) to Equal Weight from Overweight with a price target of $22, down from $38.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes downgraded to Market Perform from Outperform at Bernstein
- Tandem Diabetes price target lowered to $53 from $60 at Barclays
- Tandem Diabetes Care: Record Sales and Strategic Growth
- Tandem Diabetes price target lowered to $55 from $65 at RBC Capital
- Tandem Diabetes price target lowered to $33 from $37 at Baird